Larimar Therapeutics Is Maintained at Outperform by Baird
DO Dow Jones Newswires Larimar Therapeutics Is Maintained at Outperform by Baird 6/30/2026, 07:59 PM GMT+8 Dow Jones Newswires LR LRMR Larimar Therapeutics Is Maintained at Outperform by Baird Market News Stocktwits LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns Dow Jones Newswires Larimar Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy Quartr LRMR: Nomlabofusp shows sustained efficacy and safety in FA, with BLA submission and phase III underway Quartr LRMR: Nomlabofusp shows sustained frataxin increases and clinical benefit in Friedreich's ataxia
